Cardene I.V. (nicardipine hydrochloride) Premixed Injection

Cardene I.V. is the only FDA-approved premixed formulation of nicardipine hydrochloride.
Prroduct image of Cardene I.V.

Indication

Cardene I.V. (nicardipine hydrochloride) Premixed Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits. Please read the accompanying full Indication(s) and Important Risk Information and full Prescribing Information.

A close up of a doctor's face in a hospital room

Rapid Acting and Titrated1

Cardene I.V. is the only FDA-approved premixed formulation of nicardipine hydrochloride and can be stored at the point of care at room temperature of 68-77oF (20-25oC) in its original carton and protected from light until its administration.1  Cardene I.V. (nicardipine HCl) acts rapidly2 and blood pressure begins to fall within minutes, and the formulation allows for rapid (q 5 min) or gradual (q 15 min) titration.1

Manufacturer-prepared premixed

Ready to administer bags

Two-year shelf life at room temperature

Can be stored at point of care

Store in carton to protect from light until ready to use
 


 

Male doctor talking to a male patient lying in a hospital bed

An antihypertensive agent that fits your patients’ needs

Cardene I.V. has documented efficacy in different clinical settings in treating patients with acute severe hypertension or acute postoperative hypertension.1

    A close up of a doctor's face in a hospital room

    Selected Important Risk Information

    Cardene I.V. is contraindicated in patients with advanced aortic stenosis.

    ● Hypotension and reflex tachycardia may potentially occur during treatment with Cardene I.V.; therefore, close monitoring of blood pressure and heart rate is required. If unacceptable hypotension or tachycardia occurs, the infusion should be discontinued.

    Please read the accompanying full Indication(s) and Important Risk Information and full Prescribing Information.

    Explore Our Related Products

    Indication and Important Safety Information for Cardene I.V.

    Indication

    CARDENE I.V. (nicardipine hydrochloride) Premixed Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits.

    Safety Information

    CARDENE I.V. is contraindicated in patients with advanced aortic stenosis.

    Hypotension and reflex tachycardia may potentially occur during treatment with CARDENE I.V.; therefore, close monitoring of blood pressure and heart rate is required. If unacceptable hypotension or tachycardia occurs, the infusion should be discontinued.

    Slow titration of CARDENE I.V. is recommended in patients with heart failure or significant left ventricular dysfunction, particularly in combination with a beta-blocker.

    Close monitoring of response to CARDENE I.V. is advised in patients with angina, heart failure, impaired hepatic function, or renal impairment.

    CARDENE I.V. may elevate serum concentrations of cyclosporine or tacrolimus. Serum concentrations of cyclosporine or tacrolimus should be monitored during co-administration with CARDENE I.V.

    To reduce the possibility of venous thrombosis, phlebitis, local irritation, and extravasation, administer CARDENE I.V. through large peripheral veins or central veins rather than arteries or small peripheral veins. If CARDENE I.V. is administered in a peripheral vein, to minimize the risk of venous irritation, change the site of infusion every 12 hours.

    The most common adverse reactions (>3%) are headache, nausea/vomiting, hypotension, and tachycardia.

    Please click here for full Prescribing Information.